Effects of low-flow sevoflurane anesthesia on renal function: comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia.
暂无分享,去创建一个
[1] M. W. Anders,et al. Cysteine Conjugate beta-Lyase-dependent Biotransformation of the Cysteine S-Conjugates of the Sevoflurane Degradation Product Compound A in Human, Nonhuman Primate, and Rat Kidney Cytosol and Mitochondria , 1996, Anesthesiology.
[2] E. Eger,et al. Metabolism of Compound A by Renal Cysteine-S-Conjugate beta-Lyase Is Not the Mechanism of Compound A-Induced Renal Injury in the Rat , 1996, Anesthesia and analgesia.
[3] T. Baillie,et al. Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. , 1996, Chemical research in toxicology.
[4] K. Ikeda,et al. Renal and Hepatic Function in Surgical Patients After Low-Flow Sevoflurane or Isoflurane Anesthesia , 1996, Anesthesia and analgesia.
[5] H. Higuchi,et al. Renal Function in Patients with High Serum Fluoride Concentrations after Prolonged Sevoflurane Anesthesia , 1995, Anesthesiology.
[6] M. Laster,et al. Nephrotoxicity in Rats Undergoing a One-Hour Exposure to Compound A , 1995, Anesthesia and analgesia.
[7] K. Ikeda,et al. Effect of total flow rate on the concentration of degradation products generated by reaction between sevoflurane and soda lime. , 1995, British Journal of Anaesthesia.
[8] T. Baillie,et al. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. , 1995, Biochemical and biophysical research communications.
[9] K. Ikeda,et al. Plasma Inorganic Fluoride and Intracircuit Degradation Product Concentrations in Long‐Duration, Low‐Flow Sevoflurane Anesthesia , 1994, Anesthesia and analgesia.
[10] K. Ikeda,et al. Long‐duration, Low‐flow Sevoflurane Anesthesia Using Two Carbon Dioxide Absorbents: Quantification of Degradation Products in the Circuit , 1994, Anesthesiology.
[11] E. Eger,et al. Toxicity of Compound A in Rats: Effect of a 3‐Hour Administration , 1994, Anesthesiology.
[12] E. Eger,et al. Toxicity of Compound A in Rats: Effect of Increasing Duration of Administration , 1994, Anesthesiology.
[13] E. Eger,et al. The Degradation, Absorption, and Solubility of Volatile Anesthetics in Soda Lime Depend on Water Content , 1994, Anesthesia and analgesia.
[14] K. Ikeda,et al. Closed‐circuit Anesthesia with Sevoflurane in Humans Effects on Renal and Hepatic Function and Concentrations of Breakdown Products with Soda Lime in the Circuit , 1994, Anesthesiology.
[15] Y. Ogasawara,et al. Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. , 1992, Anesthesiology.
[16] R. Mazze. The safety of sevoflurane in humans. , 1992, Anesthesiology.
[17] M. Malcomson,et al. Quantification of the degradation products of sevoflurane in two CO2 absorbants during low-flow anesthesia in surgical patients. , 1992, Anesthesiology.
[18] E. Eger,et al. Absorption and Degradation of Sevoflurane and Isoflurane in a Conventional Anesthetic Circuit , 1991, Anesthesia and analgesia.
[19] H. Shimada,et al. Effect of N-benzyl-D-glucamine dithiocarbamate on renal toxicity of inorganic mercury in rats. , 1990, Chemical & pharmaceutical bulletin.
[20] Jerome J. Schentag,et al. The Increase in Urinary Alanine Aminopeptidase Excretion Associated with Enflurane Anesthesia Is Increased Further by Aminoglycosides , 1988, Anesthesia and analgesia.
[21] K. Ikeda,et al. The Minimum Alveolar Concentration (MAC) of Sevoflurane in Humans , 1987, Anesthesiology.
[22] R. Gibey,et al. Urinary N-acetyl-beta-D-glucosaminidase (NAG) isoenzyme profiles: a tool for evaluating nephrotoxicity of aminoglycosides and cephalosporins. , 1984, Clinica chimica acta; international journal of clinical chemistry.
[23] P. Kind. N-Acetyl-beta-D-glucosaminidase in urine of patients with renal disease, and after renal transplants and surgery. , 1982, Clinica chimica acta; international journal of clinical chemistry.
[24] R. Gibey,et al. Predictive value of urinary N-acetyl-beta-D-glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobulin (beta 2M) in evaluating nephrotoxicity of gentamicin. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[25] T. Maekawa,et al. Clinical evaluation of urinary N-acetyl-beta-D-glucosaminidase activity in patients receiving aminoglycoside and cephalosporin drugs. , 1981, Research communications in chemical pathology and pharmacology.
[26] R. G. Price,et al. Urinary enzyme excretion during renal papillary necrosis induced in rats with ethyleneimine. , 1975, Chemico-biological interactions.
[27] I. Stern,et al. Sevoflurane: A New Inhalational Anesthetic Agent , 1975, Anesthesia and analgesia.
[28] R. G. Price,et al. Automated assay of N-acetyl-beta-glucosaminidase in normal and pathological human urine. , 1975, Clinica chimica acta; international journal of clinical chemistry.
[29] R. Elashoff,et al. Minimum alveolar concentrations (MAC) of isoflurande with and without nitrous oxide in patients of various ages. , 1975, Anesthesiology.